RE:RE:RE:RE:RE:RE:RE:RE:LOI CarrTripp said this deal and working with Care has been in the works for over a year.
As business men they know that the share price will fluctuate. They likely would have gone to their referral network to confirm the interest and verify the clinical data on Aristotle testing to ensure it was the right opportunity. Why else would they accept shares and not a cash deal? They spent years building a company, putting their names and reputations behind it to sell it for a share only deal that some would have you believe is only worth $.30 a share. LOL. Come on. These are experts in the oncology and inflamation disease areas and they agreed to an all share deal without doing their DD on long term valuation here.
It amazes me how people on this board with zero business acumen can armchair quarterback on a deal that was worked on for a year.
Did you see Jack Lifton's reaction to learn about Aristotle and the market opportunities. An experienced investor who sees the potential. The Care Oncology team obviously see the long term potential and value of the all share deal. But no lets listen to these bashers and soft bashers based on their feelings. LOL
Notice how the bashers are trying to bury the posts on the fact that the share price is irrelevant and that the deal is not based on share price. They are trying to create doubt and fear but in reality, Stage has cash in the bank, increasing revenues and an upcoming deal to close on Care Oncology.
Q. Is there a share price associated with the deal?
A. There is not a share price associated with the deal. The acquisition is an all-share deal and not underpinned by a share price
Liked2Think wrote: In life and business it really all comes down to who you know.
I was against the CAre thing to begine with but the company is made up of cancer pros that have years of experience and they made something of their buisness
Its nice to think about all the contacts they have made while building their business, going through schooling, etc